Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-1 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). This concludes enrollment in the Phase 3 ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) program. Top-line data are expected from ENHANCE-2 in the third quarter of 2022 and from ENHANCE-1 around the end of 2022.
